Evaluation of Medication Adherence and Pharmacokinetics of Dasatinib for Earlier Molecular Response in Japanese Patients With Newly Diagnosed Chronic Myeloid Leukemia: A Pilot Study-Reference-Cited by-同舟云学术

Evaluation of Medication Adherence and Pharmacokinetics of Dasatinib for Earlier Molecular Response in Japanese Patients With Newly Diagnosed Chronic Myeloid Leukemia: A Pilot Study

Published:2019-10 Issue:5 Volume:41 Page:575-581
ISSN:0163-4356
Container-title:Therapeutic Drug Monitoring
language:en
Short-container-title:

Author:

Iwamoto Takuya,Monma Fumihiko,Ohishi Kohshi,Umino Akira,Suzuki Kei,Oka Koji,Kawakami Keiki,Sekine Takao,Okuda Masahiro,Katayama Naoyuki

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Pharmacology

Reference27 articles.

1. European LeukemiaNet recommendations for the management of chronic myeloid leukemia;Baccarani;Blood.,2013

2. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia;Saglio;N Engl J Med.,2010

3. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia;Kantarjian;N Engl J Med.,2010

4. Imatinib treatment in chronic myelogenous leukemia: what have we learned so far?;Breccia;Cancer Lett.,2011

5. Medication adherence to tyrosine kinase inhibitors: 2-year analysis of medication adherence to imatinib treatment for chronic myeloid leukemia and correlation with the depth of molecular response;Santoleri;Acta Haematol.,2016

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessing and mitigating pH-mediated DDI risks in drug development – formulation approaches and clinical considerations;Drug Metabolism Reviews;2024-05-03

2. Therapeutic Drug Monitoring and Individualized Medicine of Dasatinib: Focus on Clinical Pharmacokinetics and Pharmacodynamics;Frontiers in Pharmacology;2021-12-06

3. Dasatinib;Reactions Weekly;2020-03

4. Novel high-performance liquid chromatography–tandem mass spectrometry method for simultaneous quantification of BCR-ABL and Bruton’s tyrosine kinase inhibitors and their three active metabolites in human plasma;Journal of Chromatography B;2020-01